Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 3—March 2005

Dispatch

Inquilinus limosus in Patients with Cystic Fibrosis, Germany

Nele Wellinghausen*Comments to Author , Andreas Essig*, and Olaf Sommerburg*
Author affiliations: *University of Ulm, Ulm, Germany

Main Article

Table

Antimicrobial susceptibility of Inquilinus limosus strains

Antimicrobial agent MIC (µg/mL)
Isolate A-1 Isolate A-2 Isolate A-3 Isolate B LMG 20952T
Trimethoprim/sulfamethoxazole >32 >32 >32 >32 >32
Amikacin 8 32 32 >256 >256
Gentamicin 8 16 12 >256 12
Tobramycin >256 >256 >256 >256 >256
Ampicillin >256 >256 >256 >256 >256
Piperacillin/tazobactam >256 >256 >256 >256 >256
Cefotaxime >32 >32 >32 >32 >32
Ceftazidime 4 4 4 0.5 32
Imipenem 0.012 0.012 0.016 0.006 0.016
Ciprofloxacin 0.032 0.032 0.032 0.500 0.064
Colistin* Resistant Resistant Resistant Resistant Resistant

*Susceptibility testing done by disk diffusion (see text); no zone of inhibition was seen.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO